Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study

Abstract Previous studies have reported conflicting results on the predictive role of the platelet-to-lymphocyte ratio (PLR) in detecting clinically significant prostate cancer (CSPCa) at the time of prostate biopsies. We explored the predictive value of pre-biopsy PLRs for CSPCa using our large-coh...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeong Woo Lee, Hyeon Jeong, Hwancheol Son, Min Chul Cho
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/dab04702858249509bfddb86aba5c1b2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:dab04702858249509bfddb86aba5c1b2
record_format	dspace
spelling	oai:doaj.org-article:dab04702858249509bfddb86aba5c1b22021-12-02T15:39:41ZPlatelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study10.1038/s41598-021-93637-32045-2322https://doaj.org/article/dab04702858249509bfddb86aba5c1b22021-07-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-93637-3https://doaj.org/toc/2045-2322Abstract Previous studies have reported conflicting results on the predictive role of the platelet-to-lymphocyte ratio (PLR) in detecting clinically significant prostate cancer (CSPCa) at the time of prostate biopsies. We explored the predictive value of pre-biopsy PLRs for CSPCa using our large-cohort database. Consecutive men with serum prostate-specific antigen (PSA) levels of ≥ 3.0 ng/mL or abnormal digital rectal examination (DRE) findings and who underwent prostate biopsies were included in the study. There was no significant difference in the pre-biopsy PLR between men with benign disease, clinically insignificant prostate cancer (CISPCa), and CSPCa. Only the subset of CSPCa patients with serum PSA levels of < 10 ng/mL showed lower PLRs than those with benign disease or CISPCa. In the entire patient cohort, multivariate analyses revealed that older age, diabetes mellitus, DRE abnormalities, higher serum PSA levels, and smaller prostate volume were predictors of CSPCa. However, the pre-biopsy PLR was not a significant predictor of CSPCa at the prostate biopsy in the entire patient cohort or the subset of patients with serum PSA levels of < 10 ng/mL. In summary, the pre-biopsy PLR is not an independent predictor of CSPCa at the prostate biopsy, regardless of the serum PSA level.Jeong Woo LeeHyeon JeongHwancheol SonMin Chul ChoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jeong Woo Lee Hyeon Jeong Hwancheol Son Min Chul Cho Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study
description	Abstract Previous studies have reported conflicting results on the predictive role of the platelet-to-lymphocyte ratio (PLR) in detecting clinically significant prostate cancer (CSPCa) at the time of prostate biopsies. We explored the predictive value of pre-biopsy PLRs for CSPCa using our large-cohort database. Consecutive men with serum prostate-specific antigen (PSA) levels of ≥ 3.0 ng/mL or abnormal digital rectal examination (DRE) findings and who underwent prostate biopsies were included in the study. There was no significant difference in the pre-biopsy PLR between men with benign disease, clinically insignificant prostate cancer (CISPCa), and CSPCa. Only the subset of CSPCa patients with serum PSA levels of < 10 ng/mL showed lower PLRs than those with benign disease or CISPCa. In the entire patient cohort, multivariate analyses revealed that older age, diabetes mellitus, DRE abnormalities, higher serum PSA levels, and smaller prostate volume were predictors of CSPCa. However, the pre-biopsy PLR was not a significant predictor of CSPCa at the prostate biopsy in the entire patient cohort or the subset of patients with serum PSA levels of < 10 ng/mL. In summary, the pre-biopsy PLR is not an independent predictor of CSPCa at the prostate biopsy, regardless of the serum PSA level.
format	article
author	Jeong Woo Lee Hyeon Jeong Hwancheol Son Min Chul Cho
author_facet	Jeong Woo Lee Hyeon Jeong Hwancheol Son Min Chul Cho
author_sort	Jeong Woo Lee
title	Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study
title_short	Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study
title_full	Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study
title_fullStr	Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study
title_full_unstemmed	Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study
title_sort	platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: a large cohort study
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/dab04702858249509bfddb86aba5c1b2
work_keys_str_mv	AT jeongwoolee platelettolymphocyteratioisnotapredictorofclinicallysignificantprostatecancerattheprostatebiopsyalargecohortstudy AT hyeonjeong platelettolymphocyteratioisnotapredictorofclinicallysignificantprostatecancerattheprostatebiopsyalargecohortstudy AT hwancheolson platelettolymphocyteratioisnotapredictorofclinicallysignificantprostatecancerattheprostatebiopsyalargecohortstudy AT minchulcho platelettolymphocyteratioisnotapredictorofclinicallysignificantprostatecancerattheprostatebiopsyalargecohortstudy
_version_	1718385903628451840

Platelet-to-lymphocyte ratio is not a predictor of clinically significant prostate cancer at the prostate biopsy: A large cohort study

Ejemplares similares